Glancy Prongay & Murray Reminds Investors of the July 6, 2015 Deadline in the Class Action Lawsuit Against Insulet Corp.

Glancy Prongay & Murray reminds investors that a class action has been filed on behalf of investors in Insulet Corp. (“Insulet” or the “Company”) (NASDAQ: PODD), who purchased Insulet securities between February 27, 2013 and April 30, 2015, inclusive (the “Class Period”). Insulet investors have until July 6, 2015 to file a lead plaintiff motion.

Insulet is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the “OmniPod System”), an insulin infusion system for people with insulin-dependent diabetes.

The complaint filed against the Company alleges that Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company was experiencing slower demand for its products; (2) that the Company was facing issues with its sales and marketing efforts; (3) that, as a result, the Company experienced unevenness in its financial performance; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects lacked a reasonable basis. As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s securities after disclosing the decline in its revenues, investors have suffered significant losses and damages.

If you purchased Insulet shares or have information or would like to learn more about these claims, or have any questions concerning this announcement, please contact Lesley Portnoy, of Glancy Prongay & Murray, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [e-mail], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701006740/en/

Glancy Prongay & Murray, Los AngelesLesley Portnoy310-201-9150 or [e-mail]